478 related articles for article (PubMed ID: 29540589)
1. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
2. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
3. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
[TBL] [Abstract][Full Text] [Related]
5. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
6. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
[TBL] [Abstract][Full Text] [Related]
7. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
[TBL] [Abstract][Full Text] [Related]
8. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
[TBL] [Abstract][Full Text] [Related]
9. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
[TBL] [Abstract][Full Text] [Related]
10. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
[TBL] [Abstract][Full Text] [Related]
11. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
[TBL] [Abstract][Full Text] [Related]
12. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö
J Neurol; 2020 Jan; 267(1):192-202. PubMed ID: 31612322
[TBL] [Abstract][Full Text] [Related]
13. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
15. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
Bajrami A; Pitteri M; Castellaro M; Pizzini F; Romualdi C; Montemezzi S; Monaco S; Calabrese M
J Neurol; 2018 Sep; 265(9):2154-2161. PubMed ID: 29938336
[TBL] [Abstract][Full Text] [Related]
16. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R
PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
Sacco R; Bisecco A; Corbo D; Della Corte M; d'Ambrosio A; Docimo R; Gallo A; Esposito F; Esposito S; Cirillo M; Lavorgna L; Tedeschi G; Bonavita S
J Neurol; 2015 Jul; 262(7):1691-7. PubMed ID: 25957638
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal changes of deep gray matter shape in multiple sclerosis.
Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
[TBL] [Abstract][Full Text] [Related]
19. Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
Uddin MN; Lebel RM; Seres P; Blevins G; Wilman AH
Mult Scler; 2016 Aug; 22(9):1133-43. PubMed ID: 26503237
[TBL] [Abstract][Full Text] [Related]
20. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
Zivadinov R; Bergsland N; Hagemeier J; Carl E; Kolb H; Hojnacki D; Weinstock-Guttman B
J Neurol Sci; 2018 May; 388():175-181. PubMed ID: 29627017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
